15+
Years experience
7
Articles
4
Specialties
Reviewer
Editorial role
About
Jane Novak is the senior medical reviewer for clinical content on Health Portal. The role oversees every medication monograph, side-effect profile, dosing guide, and clinical-data summary published on the site — verifying that claims match FDA prescribing information, current peer-reviewed evidence, and recognized treatment guidelines.
Her clinical focus is endocrinology and obesity medicine, with particular interest in GLP-1 receptor agonists, GLP-1/GIP dual agonists, and the emerging triple-agonist class. She has reviewed approximately 30 clinical pages on Health Portal covering semaglutide, tirzepatide, orforglipron, and oral semaglutide.
Editorial review philosophy: every clinical claim should cite a primary source (NEJM, Lancet, FDA documents, peer-reviewed trial data) — not other secondary publications. Where evidence is preliminary or conflicting, the reviewer's job is to make that uncertainty visible to the reader.
Specialties
- Endocrinology
- Type 2 diabetes
- Obesity medicine
- GLP-1 therapeutics
Education
- MD—Johns Hopkins School of Medicine(2010)
- MPH (Health Policy)—Harvard T.H. Chan School of Public Health(2012)
- Endocrinology Fellowship—Massachusetts General Hospital(2017)
Affiliations & memberships
- Member · American Association of Clinical Endocrinology (AACE)
- Member · The Obesity Society (TOS)
- Member · American Diabetes Association (ADA)
Articles reviewed Jane Novak
7 reviewed articles on Health Portal.
Medication
Foundayo (orforglipron): the first oral GLP-1 pill
ReadMedication
Oral Wegovy: the semaglutide pill
ReadSide effects
Foundayo side effects: incidence + management
ReadSide effects
Oral Wegovy side effects
ReadComparison
GLP-1 vs GLP-1/GIP: mechanism + outcomes
ReadCoverage
Medicare GLP-1 Bridge program 2026
ReadCoverage
GLP-1 insurance appeal guide
Read